Cover Image
市場調查報告書

膀胱過動症治療的全球市場

Global Overactive Bladder Therapeutics Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 318306
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
Back to Top
膀胱過動症治療的全球市場 Global Overactive Bladder Therapeutics Market 2014-2018
出版日期: 2014年11月05日 內容資訊: 英文 91 Pages
簡介

膀胱過動症是排尿障礙伴隨的泌尿系統疾病,突然的尿急、排尿間隔的變化、夜間頻尿、尿失禁等膀胱積蓄尿的功能相關症狀為特徵。雖然不是危及生命的疾病,但常讓人感到丟臉、氣力減退等症狀。全球膀胱過動症治療市場,預計從2013年到2018年期間年複合成長率成長1.14%。

本報告提供全球膀胱過動症治療市場相關調查分析、市場概要、市場區隔考察、各地區考察、推動市場的要素與課題、主要企業等相關彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 報告的範圍

  • 市場概要
  • 商品一覽

第4章 產品簡介

第5章 市場調查的方法

  • 市場調查的流程
  • 調查方法

第6章 簡介

第7章 市場概要

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 市場區隔:各分子類型

  • 生技藥品
  • 小分子

第9章 市場區隔:各服藥方法

  • 口服
  • 非口服
  • 局部

第10章 市場區隔:各藥物群

  • 抗蠅蕈鹼製劑
  • β3腎上腺素受體促效劑

第11章 市場區隔:各劑型

  • 固態
  • 液狀
  • 半固態
  • 經皮

第12章 發病率和患病數

第13章 各地區市場區隔

第14章 購買標準

第15章 市場成長的促進要素

第16章 促進要素與其影響

第17章 市場課題

第18章 促進要素與課題的陰影

第19章 市場趨勢

第20章 趨勢與其影響

第21章 供應商狀況

  • 競爭模式
  • 市場佔有率分析
  • 其他主要供應商

第22章 開發平台組合

第23章 主要供應商分析

  • Actavis plc
  • Allergan Inc.
  • Astellas Pharma
  • Pfizer

第24章 本系列的其他報告

目錄
Product Code: IRTNTR4514

About Overactive Bladder

Overactive bladder is a urological condition associated with urination problems. The condition is characterized by bladder storage symptoms such as urgency, change in frequency of urination, nocturia, or urinary incontinence. It is also known as overactive bladder syndrome. Although it is not a life-threatening condition, it is often stigmatized and debilitating. Some of the important symptoms of overactive bladder are urinary urgency and incontinence. The pathophysiology of overactive bladder is not characterized completely. The symptoms of overactive bladder can last for a lifetime or it can relapse and remit. The problem can be resolved through treatment. Overactive bladder can affect a person irrespective of the gender. The reason is the abnormal contraction of the urinary detrusor muscle of the bladder. In addition, overactive bladder can be related to neurological diseases such as Parkinson's disease and multiple sclerosis.

TechNavio's analysts forecast the Global Overactive Bladder Therapeutics market to grow at a CAGR of 1.14 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Overactive Bladder Therapeutics market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of overactive bladder, which include:

  • Anti-muscarinic Agent
  • Beta-3-Adrenergic Receptor Agonist

TechNavio's report, Global Overactive Bladder Therapeutics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Overactive Bladder Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • Allergan
  • Astellas Pharma
  • Pfizer

Other Prominent Vendors

  • Addex Therapeutics
  • AltheRx Pharmaceuticals
  • American Oriental Bioengineering
  • Antares Pharma
  • Apogepha Arzneimittel
  • Auxilium Pharmaceuticals
  • Bayer
  • elbion
  • FemmePharma
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Hisamitsu Pharmaceutical
  • Hydra Biosciences
  • Ion Channel Innovations
  • Ipsen
  • Janssen
  • Kissei Pharma
  • Kwang Dong Pharmaceutical
  • KYORIN Pharma
  • Laboratorios SALVAT
  • LG Life Sciences
  • Lipella Pharmaceuticals
  • Merck
  • Motif BioSciences
  • Mylan
  • Novartis
  • Ono Pharmaceuticals
  • Ranbaxy Laboratories
  • Recordati
  • Sanofi
  • Sunovion
  • Takeda Pharmaceutical
  • TARIS BioMedical
  • Teva Pharmaceutical
  • TheraVida
  • Toray Industries
  • Urigen Pharmaceuticals

Market Driver

  • Rise in Geriatric Population
  • For a full, detailed list, view our report

Market Challenge

  • Difficulty in Disease Diagnosis
  • For a full, detailed list, view our report

Market Trend

  • Increase in Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Enablex/Emselex
    • 04.1.2. Gelnique
    • 04.1.3. Oxytrol
    • 04.1.4. Botox
    • 04.1.5. Sanctura/ Sanctura XR
    • 04.1.6. Myrbetriq
    • 04.1.7. Vesicare
    • 04.1.8. Detrol/Detrol LA
    • 04.1.9. Toviaz

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Molecule Type

  • 08.1. Biologics
  • 08.2. Small Molecules

09. Market Segmentation by Route of Administration

  • 09.1. Oral
  • 09.2. Parenteral
  • 09.3. Topical

10. Market Segmentation by Class of drugs

  • 10.1. Anti-muscarinic Agent
  • 10.2. Beta-3-Adrenergic Receptor Agonist

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid
  • 11.3. Semisolid
  • 11.4. Transdermal

12. Rate of Incidence and Prevalence

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2013
    • 21.2.1. Actavis
    • 21.2.2. Allergan
    • 21.2.3. Astellas Pharma
    • 21.2.4. Pfizer
  • 21.3. Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

  • 23.1. Actavis plc
    • 23.1.1. Key Facts
    • 23.1.2. Business Description
    • 23.1.3. Business Segmentation
    • 23.1.4. Business Segmentation by Revenue 2012 and 2013
    • 23.1.5. Sales by Geography
    • 23.1.6. Business Strategy
    • 23.1.7. Key Information
    • 23.1.8. SWOT Analysis
  • 23.2. Allergan Inc.
    • 23.2.1. Key Facts
    • 23.2.2. Business Description
    • 23.2.3. Business Segmentation
    • 23.2.4. Revenue by Business Segmentation
    • 23.2.5. Revenue Comparison 2011-2013
    • 23.2.6. Revenue by Geographical Segmentation
    • 23.2.7. Business Strategy
    • 23.2.8. Key Developments
    • 23.2.9. SWOT Analysis
  • 23.3. Astellas Pharma
    • 23.3.1. Key Facts
    • 23.3.2. Business Overview
    • 23.3.3. Product Segmentation
    • 23.3.4. Product Segmentation by Revenue 2012 and 2013
    • 23.3.5. Geographical Segmentation by Revenue 2013
    • 23.3.6. Business Strategy
    • 23.3.7. Recent Developments
    • 23.3.8. SWOT Analysis
  • 23.4. Pfizer
    • 23.4.1. Key Facts
    • 23.4.2. Business Overview
    • 23.4.3. Business Segmentation by Revenue 2013
    • 23.4.4. Business Segmentation by Revenue 2012 and 2013
    • 23.4.5. Geographical Segmentation by Revenue
    • 23.4.6. Business Strategy
    • 23.4.7. Key Developments
    • 23.4.8. SWOT Analysis

24. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Overactive Bladder Therapeutics Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type
  • Exhibit 4: Global Overactive Bladder Therapeutics Market Segmentation by Molecule Type 2013
  • Exhibit 5: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration
  • Exhibit 6: Global Overactive Bladder Therapeutics Market Segmentation by Route of Administration 2013
  • Exhibit 7: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs
  • Exhibit 8: Global Overactive Bladder Therapeutics Market Segmentation by Class of Drugs 2013
  • Exhibit 9: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form
  • Exhibit 10: Global Overactive Bladder Therapeutics Market Segmentation by Dosage Form 2013
  • Exhibit 11: Global Overactive Bladder Therapeutics Market by Geographical Segmentation 2013
  • Exhibit 12: Global Overactive Bladder Therapeutics Market Share Analysis 2013
  • Exhibit 13: Prescription chart
  • Exhibit 14: By drugs prescribed (up to 2011)
  • Exhibit 15: YoY Sales Comparison of Botox 2008-2013 (in US$ million)
  • Exhibit 16: YoY Sales Comparison of Vesicare 2008-2013 (in US$ million)
  • Exhibit 17: YoY Sales Comparison of Vesicare in Japan 2008-2013 (in US$ million)
  • Exhibit 18: YoY Sales Comparison of Vesicare in the Americas 2008-2013 (in US$ million)
  • Exhibit 19: YoY Sales Comparison of Vesicare in Europe 2008-2013 (in US$ million)
  • Exhibit 20: YoY Sales Comparison of Vesicare in Asia 2008-2013 (in US$ million)
  • Exhibit 21: Sales Comparison of Vesicare 2008-2013 (in US$ million)
  • Exhibit 22: YoY Sales Comparison of Detrol/Detrol LA 2009-2013 (in US$ million)
  • Exhibit 23: YoY Sales Comparison of Toviaz 2009-2013 (in US$ million)
  • Exhibit 24: Pipeline Molecules for the Treatment of Overactive Bladder
  • Exhibit 25: Global Overactive Bladder Therapeutics Market Business Segmentation 2013
  • Exhibit 26: Global Overactive Bladder Therapeutics Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 27: Actavis Plc: Sales by Geography (in US$ million)
  • Exhibit 28: Allergan Inc.: Business Segmentation
  • Exhibit 29: Allergan Inc.: Revenue by Business Segmentation 2013
  • Exhibit 30: Allergan Inc.: Revenue Comparison by Business Segmentation 2011-2013 (US$ billion)
  • Exhibit 31: Allergan Inc.: Revenue by Geographical Segmentation 2013
  • Exhibit 32: Astellas Pharma: Product Segmentation 2013
  • Exhibit 33: Astellas Pharma: Product Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 34: Astellas Pharma: Geographical Segmentation by Revenue 2013
  • Exhibit 35: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 36: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 37: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top